Phase 1/2 Glioblastoma Multiforme Study Underway

Andrew Black
Published Online: Thursday, Feb 16, 2017
Biopharmaceutical company Berg has initiated their Phase 1/2 trial for BPM 31510-IV, a potential treatment of Glioblastoma Multiforme (GBM).
The trial is an open-label, non-randomized clinical trial that is designed to evaluate the safety and tolerability of BPM 31510-IV in patients with GBM that has recurred on a bevacizumab-containing regimen.
Patients will receive BPM 31510 injectable nanosuspension IV over 72 hours twice weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The trial will take place at the Stanford University School of Medicine. It is currently enrolling patients, to find out more information or to enroll, visit
BPM 31510-IV is designed to slow or stop cancer cell growth by reversing the compromised metabolism of cancer cells.
It is also in a Phase 2 clinical trial for advanced pancreatic cancer.

About Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is a rare but very aggressive form of brain cancer. Glioblastomas can be classified as primary or secondary. Primary glioblastoma tends to occur in older adults (> 50 years) and appear quite suddenly (less than 3 months from initial symptoms to diagnosis). Secondary glioblastoma is less common and occurs in younger patients (< 45 y). These tumors can be present for years before symptoms appear.
Standard therapy for glioblastoma consists of surgical resection, radiation therapy, and chemotherapy. Patients treated with this standard therapy tend to survive for approximately 12 months. Without treatment, survival is about 3 months.

Latest Articles
The study observed that overall survival was significantly longer in the midostaurin group (74.7 months) compared to the placebo group (25.6 months; P = .009).
Even though the Duchenne drug is approved, some insurance companies want to wait until more data is available. Meanwhile, the boys waiting for the drug continue to decline.
Acceleron Pharma announced preliminary results from the ongoing Phase 2 studies of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS).
Takeda Pharmaceutical debuted data from 2 Phase 1/2 clinical trials evaluating Ninlaro (ixazomib) in newly diagnosed multiple myeloma patients.
$vacMongoViewPlus$ $vAR$